177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Condition(s):Prostatic NeoplasmsLast Updated:March 20, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Prostatic NeoplasmsLast Updated:March 20, 2024Active, not recruiting
Condition(s):Metastatic Castration-resistant Prostate CancerLast Updated:February 7, 2024Recruiting
Condition(s):Metastatic Castration Resistant Prostate CancerLast Updated:March 15, 2024Recruiting
Condition(s):Metastatic Castration-resistant Prostate Cancer; mCRPC; Prostate CancerLast Updated:October 27, 2023Recruiting
Condition(s):Metastatic Prostate Cancer; Prostate Cancer; Prostate Neoplasm; Advanced Solid Tumor; Solid TumorLast Updated:January 12, 2024Recruiting
Condition(s):Prostatic Neoplasms, Castration-ResistantLast Updated:April 23, 2021Terminated
Condition(s):Advanced Solid Tumors; CRPC; mCRPC; Metastatic Castrate-resistant Prostate Cancer; PT-112; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by SiteLast Updated:August 14, 2023Recruiting
Condition(s):Prostate CancerLast Updated:June 1, 2016Completed
Condition(s):Prostate Cancer MetastaticLast Updated:December 5, 2023Recruiting
Condition(s):Prostate CancerLast Updated:March 22, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.